

Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of HER2-Positive Breast Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was observed regarding progression-free survival (PFS) among patients with CNS disease in the Phase III NALA trial evaluating neratinib with capecitabine versus lapatinib with capecitabine for HER2-positive metastatic breast cancer?
 - a. Improvement on the neratinib arm
 - b. Similar outcomes on both arms
 - c. Improvement on the lapatinib arm
2. Which of the following conditions was reported as an adverse event in the DESTINY-Breast01 trial of trastuzumab deruxtecan for previously treated metastatic HER2-positive breast cancer?
 - a. New secondary cancer
 - b. Ocular toxicities
 - c. Interstitial lung disease
3. The results of the HER2CLIMB trial evaluating tucatinib versus placebo in combination with trastuzumab/capecitabine for patients with previously treated HER2-positive breast cancer and brain metastases demonstrated which of the following outcomes?
 - a. Similar overall survival outcomes on both study arms
 - b. Improvement in overall survival with tucatinib
4. What did the results from the Phase III KATHERINE study demonstrate regarding invasive disease-free survival with T-DM1 compared to trastuzumab as adjuvant therapy for patients with early-stage HER2-positive breast cancer and residual disease after neoadjuvant chemotherapy/trastuzumab?
 - a. Improvement with T-DM1
 - b. Improvement with trastuzumab
 - c. Similar results on both study arms
5. What did the results from the Phase III SOPHIA study demonstrate regarding PFS with margetuximab/chemotherapy compared to trastuzumab/chemotherapy for patients with previously treated HER2-positive metastatic breast cancer?
 - a. Improvement with margetuximab/chemotherapy
 - b. Improvement with trastuzumab/chemotherapy
 - c. Similar results on both study arms